REVCOVI Trademark

Trademark Overview

On Friday, January 13, 2017, a trademark application was filed for REVCOVI with the United States Patent and Trademark Office. The USPTO has given the REVCOVI trademark a serial number of 87300981. The federal status of this trademark filing is REGISTERED as of Tuesday, July 9, 2019. This trademark is owned by LEADIANT BIOSCIENCES LIMITED. The REVCOVI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of immunodeficiencies, namely, adenosine deaminase deficiency
revcovi

General Information

Serial Number87300981
Word MarkREVCOVI
Filing DateFriday, January 13, 2017
Status700 - REGISTERED
Status DateTuesday, July 9, 2019
Registration Number5800819
Registration DateTuesday, July 9, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 30, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of immunodeficiencies, namely, adenosine deaminase deficiency

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, January 21, 2017
Primary Code005
First Use Anywhere DateMonday, November 19, 2018
First Use In Commerce DateMonday, November 19, 2018

Trademark Owner History

Party NameUNIKERIS LIMITED
Party Type31 - New Owner After Registration
Legal Entity Type03 - Corporation
AddressMANCHESTER M22 5LG
GB
Party NameLEADIANT BIOSCIENCES LIMITED
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressLONDON EC1A2DY
GB
Party NameLEADIANT BIOSCIENCES LIMITED
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressLONDON EC1A2DY
GB
Party NameLEADIANT BIOSCIENCES LIMITED
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLONDON EC1A2DY
GB

Trademark Events

Event DateEvent Description
Saturday, January 21, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 17, 2017NEW APPLICATION ENTERED
Monday, April 10, 2017ASSIGNED TO EXAMINER
Monday, April 17, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 10, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 30, 2017PUBLISHED FOR OPPOSITION
Saturday, October 14, 2017CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Tuesday, November 28, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 30, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, June 15, 2017EXTENSION OF TIME TO OPPOSE RECEIVED
Thursday, September 21, 2017TEAS POST PUBLICATION AMENDMENT RECEIVED
Thursday, October 5, 2017ASSIGNED TO PETITION STAFF
Sunday, October 8, 2017EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, April 30, 2019TEAS STATEMENT OF USE RECEIVED
Tuesday, April 30, 2019USE AMENDMENT FILED
Tuesday, May 14, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, May 10, 2018SOU TEAS EXTENSION RECEIVED
Thursday, May 10, 2018SOU EXTENSION 1 FILED
Thursday, May 10, 2018SOU EXTENSION 1 GRANTED
Saturday, May 12, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 20, 2018SOU TEAS EXTENSION RECEIVED
Tuesday, November 20, 2018SOU EXTENSION 2 FILED
Tuesday, November 20, 2018SOU EXTENSION 2 GRANTED
Thursday, November 22, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 14, 2019STATEMENT OF USE PROCESSING COMPLETE
Wednesday, June 5, 2019ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, June 6, 2019NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, July 9, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, July 9, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, June 23, 2021AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

Related Keywords

revcovi adenosine deaminase deficiency namely immunodeficiencies preparations treatment pharmaceutical